Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : IGT Pharma (V.IGT) Anti-Cancer Blockbuster!! -- Ignore unavailable to you. Want to Upgrade?

To: BobBeaty who wrote (43)	12/29/1998 10:56:00 AM
From: Spiney	Read Replies (1) \| Respond to of 86

IGT Pharma receives authorization to start human trial IGT Pharma Inc IGT Shares issued 8,819,820 Dec 24 close $0.77 Tue 29 Dec 98 News Release Mr. Bruce Schmidt reports IGT has received authorization from the Therapeutic Products Program of Health Canada to start a phase 1 human clinical trial using the new cancer drug, Anhydrovinblastine. The approval, received in the form of a letter of no objection, allows for the immediate staging of all aspects of the study. The purpose of a phase 1 clinical trial is to determine the safety and dose ranging factors that will lead to the optimum dose level for treating patients in subsequent studies. Whereas the phase 1 study will involve a maximum of 30 patients who may have various forms of cancer, further studies will involve only patients with non-small call lung cancer. Lung cancer is the most common form of cancer in the United States, with over 75 per cent of those cases being the non-small cell type. The commencement of human clinical trials is a significant milestone for companies such as IGT as it is typically when major pharmaceutical companies develop an active interest in new cancer products. Partnership with these multi-national companies would provide IGT with return on investment through licencing fees, marketing rights and involvement in latter stage clinical trials. In addition to AVLB, the company has recently started the development of its second cancer drug targeted at drug resistant cancers. Areas of neurological drug development include the treatment of schizophrenia, anxiety, stroke and epilepsy. (c) Copyright 1998 Canjex Publishing Ltd. canada-stockwatch.com ------------------------- don't know why they announced this...? the company says they are waiting for FDA approval which should come any day now. my apologies if this prints a few times - I'm having problems connecting to SI this morning.